AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases

With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases, the companies announced Thursday.